Huons Meditech Secures NMPA Approval for Premium 9Pin Needle in China's Aesthetic Market
核心洞察
Huons Meditech (搜索) received regulatory clearance from China's National Medical Products Administration (搜索) (NMPA) for its Premium 9Pin Needle (搜索) designed for skin booster treatments.
The specialized needle features precision-engineered structure that enhances stability under high-pressure injection and optimizes delivery of high-viscosity substances deep into skin without leakage.
The approval marks a key expansion step for the Korea-based medical device firm into China's fast-growing cosmetic procedures market.
Huons Meditech (搜索) has secured regulatory approval from China's National Medical Products Administration (搜索) (NMPA) for its Premium 9Pin Needle (搜索), marking the Korea-based medical device company's entry into China's rapidly expanding cosmetic procedures market.
The company announced Wednesday that it recently completed registration with the NMPA for the specialized injection needle designed for skin booster treatments, representing a significant milestone in its international expansion strategy.
Technical Innovation and Design Features
The Premium 9Pin Needle (搜索) incorporates several advanced design elements aimed at improving treatment efficacy and safety. According to the company, the needle features a precision-engineered structure that enhances stability even under high-pressure injection conditions.
The device's design optimizes the needle's inner diameter length, enabling high-viscosity substances to be delivered deep into the skin without leakage, thereby reducing drug loss during procedures. This technical advancement addresses a common challenge in aesthetic treatments where substance waste can impact both treatment outcomes and cost-effectiveness.
Enhanced Safety and Patient Comfort
Huons Meditech (搜索) emphasized improvements in both patient experience and practitioner safety with the Premium 9Pin Needle (搜索). The device incorporates a specialized bevel design that minimizes pain and reduces recovery time for patients undergoing skin booster treatments.
For healthcare providers, the needle includes a dedicated protective cap designed to help prevent needle-stick injuries during procedures, addressing an important occupational safety concern in aesthetic medicine.
Integration with Proprietary Platform
The Premium 9Pin Needle (搜索) is specifically designed for use with Huons Meditech (搜索)'s proprietary injection systems, the Dermashine Pro (搜索) and Dermashine Balance (搜索). This integration creates what the company describes as a complete aesthetic treatment solution.
"By combining the globally recognized Dermashine platform with the innovative Premium 9Pin Needle (搜索), we have built a complete aesthetic treatment solution," said Huons Meditech (搜索) CEO Ha Chang-woo.
Market Expansion Strategy
The NMPA approval represents a strategic entry point for Huons Meditech (搜索) into China's cosmetic procedures market. The company views this regulatory clearance as a springboard for expanding its global market share while continuing to introduce innovative medical devices.
"With NMPA approval, we aim to strengthen our position as a trusted partner among aesthetic professionals in China," Ha Chang-woo added.
The approval positions Huons Meditech (搜索) to compete in China's growing aesthetic medicine sector, where demand for advanced injection technologies and skin enhancement procedures continues to increase.